FRM
APGE

Fox Run Management’s Apogee Therapeutics APGE Stock Holding History

Fox Run Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,371
Closed -$481K – 893
2025
Q4 		$481K Buy
+6,371
New +$401K 0.07% 521
2025
Q3 		– Sell
-10,055
Closed -$437K – 894
2025
Q2 		$437K Buy
+10,055
New +$383K 0.07% 520

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fox Run Management's APGE Position: Q1 2026 in Review

Fox Run Management sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 6,371 shares — an estimated $481K sold.

Fox Run Management first reported a position in APGE in Q2 2025 and held it in 2 quarters. The position peaked at $481K in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Fox Run Management reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 6,371 Apogee Therapeutics shares in Q1 2026, an estimated $481K.
  • Fox Run Management first reported a position in Apogee Therapeutics in Q2 2025 and held it in 2 quarters.
  • Fox Run Management's Apogee Therapeutics position peaked at $481K in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.